"Cynata’s strategy is to develop multiple candidate products in clinical indications of high unmet need. This includes common diseases affecting millions of patients worldwide. With no internal salesforce or in-house manufacturing, we aim to pursue a partnership-led model, leveraging the strengths of global collaborators to drive execution and market access.
Importantly, we are able to capitalise on years of proof-of-concept research and billions already spent by MSC peers to educate markets and validate clinical use-cases. We plan to introduce more potent, scalable, and consistent iPSC-derived MSC products into markets where demand is proven and competition remains low.
We are also operating in a market environment with accelerating tailwinds, including a global increase in MSC clinical trials now reaching maturity, increasing regulatory support through Fast Track and Orphan Drug pathways, and a rising burden of chronic disease and ageing populations that is driving growing demand for regenerative medicine solutions."
Just like MSB to its credit is poised to revolutionize the stem cell market mostly limited to date by autologous hematopoietic stem cell (HSC) transplantation for blood and immune system disorders, with at last the first approved allogeneic stem cell therapy, so IPSC's are a natural evolution of the sector again. Cynata at <$40 million mkt cap and the IPSC market leader, with a fully funded and recruited phase III trial, is cheap, cheap:
CYP Price at posting:
17.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)